Asiamet Resources Limited ( Asiamet or the Company ) is pleased to provide an update with respect to several key workstreams in progress at the BKM copper development project and the Kalimantan Suraya Kencana Contract of Work ( KSK CoW ) located in Central Kalimantan, Indonesia. Highlights · Value Enhancement works related to transitioning the BKM copper mine development from a heap leach to tank leach processing route is making solid progress. Capex and Opex estimates expected in late July will be used as inputs to update the BKM project economics. · Options for direct shipping of high grade, high value polymetallic ore from the BKZ deposit is being investigated with commodity trading companies for potential offtake or smelter feed. Required metallurgy work will be undertaken from the upcoming drilling programme.
Preoperative testing is often unnecessary for low-risk surgeries, shows study news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Before undergoing surgery, patients often go through a number of tests: blood work, sometimes a chest X-ray, perhaps tests to measure heart and lung function.
In fact, about half of patients who had one of three common surgical procedures done in Michigan between 2015 and the midway point of 2019 received at least one routine test beforehand.
Yet plenty of evidence suggests that preoperative testing is often unnecessary for low-risk surgeries.
Share this article
Share this article
DUBLIN, Feb. 11, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2020 and provided financial expectations for 2021. 2020 was a demonstration of the resiliency of our organization, as we adapted our business to endure a pandemic that has proved to be one of the most disruptive events in our recent history. Despite the challenges posed by COVID-19, we achieved significant growth of net sales from our portfolio of proprietary commercial products, advanced our pipeline of neuroscience and oncology candidates, and announced a Value Enhancement Plan designed to drive growth and improve operational and financial performance, said Richard Pops, Chief Executive Officer of Alkermes. We are focused on value creation in 2021 as we seek to grow and diversify our commercial portfolio, demonstrate the value of our R&D investments, and manage the company for growth and long-term pr